Vaxcyte (NASDAQ:PCVX) CAO Elvia Cowan Sells 2,500 Shares

Key Points

• CAO Elvia Cowan sold 2,500 shares of Vaxcyte on March 11 at an average price of $58.59 for $146,475, leaving her with 30,867 shares (a 7.49% reduction in her stake).
• Vaxcyte reported a Q (EPS) of ($1.80), missing estimates of ($1.46) and analysts expect about –4.21 EPS for the fiscal year; the stock traded near $57.53 with a 12‑month range of $27.66–$76.61.
• Analyst sentiment is positive overall with an average rating of "Moderate Buy" and a consensus price target of $94.50, while several firms (e.g., BTIG, Needham, Guggenheim) have recently raised targets or maintained "buy" ratings.

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CAO Elvia Cowan sold 2,500 shares of Vaxcyte stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $58.59, for a total transaction of $146,475.00. Following the sale, the chief accounting officer owned 30,867 shares in the company, valued at $1,808,497.53. This represents a 7.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Elvia Cowan also recently made the following trade(s):

• On Tuesday, December 23rd, Elvia Cowan sold 11,623 shares of Vaxcyte stock. The shares were sold at an average price of $47.92, for a total transaction of $556,974.16.

Vaxcyte Stock Performance

Shares of PCVX stock traded down $0.71 during mid-day trading on Wednesday, hitting $57.53. 696,500 shares of the stock were exchanged, compared to its average volume of 1,402,211. The stock's fifty day simple moving average is $53.49 and its two-hundred day simple moving average is $45.47. The stock has a market capitalization of $8.28 billion, a price-to-earnings ratio of -10.24 and a beta of 1.31. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $76.61.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing analysts' consensus estimates of ($1.46) by ($0.34). During the same period last year, the business posted ($1.12) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on PCVX. BTIG Research boosted their price objective on Vaxcyte from $85.00 to $89.00 and gave the company a "buy" rating in a research note on Wednesday, February 25th. Guggenheim restated a "buy" rating and set a $116.00 target price on shares of Vaxcyte in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a report on Friday, January 9th. Needham & Company LLC increased their price target on shares of Vaxcyte from $90.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, January 7th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Vaxcyte in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $94.50.

Institutional Trading of Vaxcyte

Hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company's stock valued at $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company's stock worth $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock worth $34,000 after purchasing an additional 184 shares during the period. Allworth Financial LP grew its position in Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company's stock valued at $44,000 after buying an additional 731 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in Vaxcyte in the 3rd quarter valued at $45,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.